Approval of Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026

Pat Growth 25pctExceptional ItemEbitda Margin CompressionResults View source PDF

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹780.00

prior close

₹801.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2+1.0+0.8+0.4-1.3-0.5-2.2-1.3-3.0-3.8+0.0-1.7+1.2—

Up moveDown movePending

AI summary

Anthem Biosciences reported strong FY2026 results with consolidated revenue from operations of Rs 2,120 crore, up 15% from Rs 1,845 crore in FY2025. Consolidated Profit After Tax grew 31% to Rs 592 crore from Rs 451 crore the prior year. The company received an unmodified (clean) audit opinion from K.P. Rao & Co. on both standalone and consolidated financials. The board recommended a final dividend of Rs 2 per share, subject to shareholder approval. Exceptional items of Rs 240 crore (standalone) and Rs 244 crore (consolidated) were recorded due to provisioning for new Indian Labour Codes. The company listed on NSE and BSE in July 2025 via an IPO.

Likely market impact

The 31% PAT growth and clean audit signal financial health. However, EBITDA margins compressed as total expenses grew faster than revenue, which investors should monitor. The ESOP allotment of 14.8 lakh shares adds to equity dilution.